Form 4: Elicio Therapeutics Director Acquires Stock Options

Robert Ruffolo, a director at Elicio Therapeutics, was granted stock options for 4,100 shares on November 21, 2024.

Summary

• Robert Ruffolo, a director of Elicio Therapeutics, received stock options for 4,100 shares of common stock.
• The options were granted on November 21, 2024, with an exercise price of $5.12 per share.
• The options will vest and become fully exercisable on the earlier of November 21, 2025, or the next annual meeting of the company's stockholders after the grant date, contingent on continued service to the company.
• The options expire on November 21, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate action (stock option grant) which is generally viewed positively as it aligns director interests with shareholders. There are no negative implications.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment from the director.

Industry Context

Stock option grants to directors are a common practice in the biotechnology industry to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly traded companies, particularly in the biotech sector.
• The vesting period of one year is fairly typical, although some companies may have longer or shorter vesting periods.
• The exercise price is set at $5.12, which is a key factor in determining the value of the options.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's performance.
• The director is incentivized to contribute to the company's success to realize the value of the options.

Key Dates

Keywords

stock options, director, Elicio Therapeutics, equity, Robert Ruffolo, vesting